# Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

> **NCT04142125** · PHASE3 · COMPLETED · sponsor: **Population Health Research Institute** · enrollment: 101 (actual)

## Conditions studied

- Ischemic Stroke
- Intracranial Atherosclerotic Disease

## Interventions

- **DRUG:** Rivaroxaban 2.5 Mg Oral Tablet bid
- **DRUG:** Acetylsalicyclic acid 81 mg tablet qd

## Key facts

- **NCT ID:** NCT04142125
- **Lead sponsor:** Population Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-03
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-09-18
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142125, "Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04142125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*